Please Wait.....
Report
Drug Overdose Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Industry Report I 2022-05-31 I 76 Pages I Global Markets Direct
Drug Overdose Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Drugs In Development, 2022, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.
Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 4, 4, 8, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Drug Overdose - Overview
Drug Overdose - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Drug Overdose - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Overdose - Companies Involved in Therapeutics Development
Amphastar Pharmaceuticals Inc
Avior Bio Inc
Clear Scientific LLC
Crossject SA
Egetis Therapeutics AB
Emergent BioSolutions Inc
Enalare Therapeutics Inc
Fab'entech SA
Hepione Therapeutics Inc
Icure Pharmaceutical Inc
InterveXion Therapeutics LLC
Klaria Pharma Holding AB
Mucodel Pharma LLC
Nasus Pharma Ltd
Opiant Pharmaceuticals Inc
Orexo AB
ResQ Pharma Inc
Sparian Biosciences Inc
Vallon Pharmaceuticals Inc
Vernalis R&D Ltd
Worphmed Srl
Drug Overdose - Drug Profiles
Antibody for Drug Overdose, Opioid Addiction and Poisoning - Drug Profile
Product Description
Mechanism Of Action
drinabant - Drug Profile
Product Description
Mechanism Of Action
History of Events
ENA-001 - Drug Profile
Product Description
Mechanism Of Action
IXTf-250 - Drug Profile
Product Description
Mechanism Of Action
IXTM-200 - Drug Profile
Product Description
Mechanism Of Action
History of Events
melatonin - Drug Profile
Product Description
Mechanism Of Action
History of Events
nalmefene - Drug Profile
Product Description
Mechanism Of Action
History of Events
nalmefene - Drug Profile
Product Description
Mechanism Of Action
History of Events
nalmefene - Drug Profile
Product Description
Mechanism Of Action
naloxone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone - Drug Profile
Product Description
Mechanism Of Action
naloxone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
naloxone hydrochloride 1 - Drug Profile
Product Description
Mechanism Of Action
naloxone. - Drug Profile
Product Description
Mechanism Of Action
History of Events
OPNT-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
physostigmine - Drug Profile
Product Description
Mechanism Of Action
PP-100 - Drug Profile
Product Description
Mechanism Of Action
SBS-371 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Acute Opioid Overdosage - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule for Drug Overdose and Drug Toxicity - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Alzheimer's Disease and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Substance Abuse and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
V-24343 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine for Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
Vaccine for Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
Drug Overdose - Dormant Projects
Drug Overdose - Discontinued Products
Drug Overdose - Product Development Milestones
Featured News & Press Releases
Apr 01, 2022: Anebulo Pharmaceuticals doses more than half of the subjects in part A of a phase 2 clinical trial and provides guidance on IND submission
Feb 08, 2022: Teva agrees to pay $225m to settle opioid claims in Texas
Jan 03, 2022: Anebulo Pharmaceuticals announces initiation of phase 2 clinical study evaluating ANEB-001 for the treatment of acute cannabinoid intoxication
Dec 20, 2021: Klaria Pharma initiates clinical study with Naloxon Alginate Film
Dec 02, 2021: Klaria Pharma receives approval to initiate clinical Phase 1 trial of Naloxone Alginate Film
Nov 16, 2021: Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124
Oct 22, 2021: Klaria Pharma announces approval by the United Stated Patent and Trademark Office of a new patent application covering naloxone alginate film
Oct 13, 2021: Anebulo Pharmaceuticals announces issuance of U.S. patent covering use of ANEB-001 for the treatment of acute Cannabinoid overdose
Sep 13, 2021: Anebulo Pharmaceuticals announces completion of manufacturing of ANEB-001 capsules for upcoming phase 2 clinical trial
Jul 16, 2021: Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial
Apr 13, 2021: Nasus Pharma announces positive results in pivotal trial of FMXIN001 Naloxone powder-based nasal spray for the treatment of opioid overdose
Feb 08, 2021: Opiant Pharmaceuticals announces first patient dosed in confirmatory pharmacokinetic study assessing OPNT003, nasal nalmefene, for the treatment of opioid overdose
Feb 05, 2021: Klaria announces patent approval in Europe of a new product patent covering Naloxone Alginate Film
Jan 29, 2021: Orexo expects FDA filing of OX124 mid 2022
Jan 27, 2021: Orexo strengthens IP rights for overdose rescue drug OX124
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Drug Overdose, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Drug Overdose - Pipeline by Amphastar Pharmaceuticals Inc, 2022
Drug Overdose - Pipeline by Avior Bio Inc, 2022
Drug Overdose - Pipeline by Clear Scientific LLC, 2022
Drug Overdose - Pipeline by Crossject SA, 2022
Drug Overdose - Pipeline by Egetis Therapeutics AB, 2022
Drug Overdose - Pipeline by Emergent BioSolutions Inc, 2022
Drug Overdose - Pipeline by Enalare Therapeutics Inc, 2022
Drug Overdose - Pipeline by Fab'entech SA, 2022
Drug Overdose - Pipeline by Hepione Therapeutics Inc, 2022
Drug Overdose - Pipeline by Icure Pharmaceutical Inc, 2022
Drug Overdose - Pipeline by InterveXion Therapeutics LLC, 2022
Drug Overdose - Pipeline by Klaria Pharma Holding AB, 2022
Drug Overdose - Pipeline by Mucodel Pharma LLC, 2022
Drug Overdose - Pipeline by Nasus Pharma Ltd, 2022
Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, 2022
Drug Overdose - Pipeline by Orexo AB, 2022
Drug Overdose - Pipeline by ResQ Pharma Inc, 2022
Drug Overdose - Pipeline by Sparian Biosciences Inc, 2022
Drug Overdose - Pipeline by Vallon Pharmaceuticals Inc, 2022
Drug Overdose - Pipeline by Vernalis R&D Ltd, 2022
Drug Overdose - Pipeline by Worphmed Srl, 2022
Drug Overdose - Dormant Projects, 2022
Drug Overdose - Discontinued Products, 2022
List of Figures
Number of Products under Development for Drug Overdose, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security